Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus | Zendy

JeanLuc Faillie | Zendy; Oriana Hoi Yun Yu | Zendy; Hui Yin | Zendy; Dominique HillaireBuys | Zendy; Alan Barkun | Zendy; Laurent Azoulay | Zendy

Open Access

Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus

Author(s) -

JeanLuc Faillie,

Oriana Hoi Yun Yu,

Hui Yin,

Dominique HillaireBuys,

Alan Barkun,

Laurent Azoulay

Publication year - 2016

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2016.1531

Subject(s) - medicine , incretin , diabetes mellitus , type 2 diabetes mellitus , exenatide , bile duct , gallbladder , gallbladder disease , gastroenterology , type 2 diabetes , general surgery , endocrinology

The use of dipeptidyl-peptidase-4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues-a group of drugs used in the management of type 2 diabetes mellitus-may be associated with an increased risk of bile duct and gallbladder disease. To date, no observational study has assessed this possible association.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research